Doris Germain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/764261/publications.pdf

Version: 2024-02-01

48 papers

2,112 citations

257450 24 h-index 233421 45 g-index

50 all docs

50 docs citations

50 times ranked

5244 citing authors

#	Article	IF	CITATIONS
1	The portrait of liver cancer is shaped by mitochondrial genetics. Cell Reports, 2022, 38, 110254.	6.4	10
2	Can THEM6 targeting stop resistance to prostate cancer treatment?. EMBO Molecular Medicine, 2022, , e15504.	6.9	1
3	Are the estrogen receptor and SIRT3 axes of the mitochondrial UPR key regulators of breast cancer subtype determination according to age?. Aging and Cancer, 2021, 2, 75-81.	1.6	2
4	Doxycycline promotes proteasome fitness in the central nervous system. Scientific Reports, 2021, 11 , 17003 .	3.3	4
5	Folding Mitochondrial-Mediated Cytosolic Proteostasis Into the Mitochondrial Unfolded Protein Response. Frontiers in Cell and Developmental Biology, 2021, 9, 715923.	3.7	8
6	Raloxifene is a Female-specific Proteostasis Therapeutic in the Spinal Cord. Endocrinology, 2021, 162 , .	2.8	5
7	Introduction to the third issue of Aging and Cancer. Aging and Cancer, 2021, 2, 74-74.	1.6	O
8	The Multi-Faced Role of PAPP-A in Post-Partum Breast Cancer: IGF-Signaling is Only the Beginning. Journal of Mammary Gland Biology and Neoplasia, 2020, 25, 181-189.	2.7	8
9	Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments?. Cancer Research, 2020, 80, 1790-1798.	0.9	41
10	Proteasome mapping reveals sexual dimorphism in tissueâ€specific sensitivity to protein aggregations. EMBO Reports, 2020, 21, e48978.	4.5	26
11	Collagen and PAPP-A in the Etiology of Postpartum Breast Cancer. Hormones and Cancer, 2019, 10, 137-144.	4.9	7
12	SOD1 is essential for oncogene-driven mammary tumor formation but dispensable for normal development and proliferation. Oncogene, 2019, 38, 5751-5765.	5.9	36
13	Mitohormesis Primes Tumor Invasion and Metastasis. Cell Reports, 2019, 27, 2292-2303.e6.	6.4	69
14	Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. Breast Cancer Research, 2019, 21, 56.	5.0	19
15	Cross talk between SOD1 and the mitochondrial UPR in cancer and neurodegeneration. Molecular and Cellular Neurosciences, 2019, 98, 12-18.	2.2	24
16	Mitohormesis, UPRmt, and the Complexity of Mitochondrial DNA Landscapes in Cancer. Cancer Research, 2019, 79, 6057-6066.	0.9	40
17	Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nature Communications, 2018, 9, 4962.	12.8	111
18	Toward the identification and the targeting of key players of the mitochondrial unfolded protein response (UPRmt) in cancer. Journal of Bioenergetics and Biomembranes, 2017, , .	2.3	3

#	Article	IF	CITATIONS
19	Patient-derived Interstitial Fluids and Predisposition to Aggressive Sporadic Breast Cancer through Collagen Remodeling and Inactivation of p53. Clinical Cancer Research, 2017, 23, 5446-5459.	7.0	14
20	Toward the identification and the targeting of key players of the mitochondrial unfolded protein response (UPRmt) in cancer. Journal of Bioenergetics and Biomembranes, 2017, 49, 291-291.	2.3	3
21	Sex specific activation of the ERÎ \pm axis of the mitochondrial UPR (UPRmt) in the G93A-SOD1 mouse model of familial ALS. Human Molecular Genetics, 2017, 26, 1318-1327.	2.9	62
22	From discovery of the CHOP axis and targeting ClpP to the identification of additional axes of the UPRmt driven by the estrogen receptor and SIRT3. Journal of Bioenergetics and Biomembranes, 2017, 49, 297-305.	2.3	19
23	mtDNA, Metastasis, and the Mitochondrial Unfolded Protein Response (UPRmt). Frontiers in Cell and Developmental Biology, 2017, 5, 37.	3.7	29
24	The Mitochondrial Unfolded Protein Response as a Non-Oncogene Addiction to Support Adaptation to Stress during Transformation in Cancer and Beyond. Frontiers in Oncology, 2017, 7, 159.	2.8	24
25	Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. Npj Breast Cancer, 2016, 2, 16037.	5.2	26
26	Mitochondrial UPR in Cancer., 2016, , 149-167.		2
27	SOD2 and the Mitochondrial UPR: Partners Regulating Cellular Phenotypic Transitions. Trends in Biochemical Sciences, 2016, 41, 568-577.	7.5	32
28	An acetyltransferase-independent function of Eso1 regulates centromere cohesion. Molecular Biology of the Cell, 2016, 27, 4002-4010.	2.1	4
29	Lactation opposes pappalysinâ€1â€driven pregnancyâ€associated breast cancer. EMBO Molecular Medicine, 2016, 8, 388-406.	6.9	41
30	Mitochondrial dysfunction in breast cancer. Research and Reports in Biology, 2015, , 137.	0.2	1
31	Cyclin D1 as a biomarker of response to fulvestrant (F) in hormone receptor-positive (HR+) breast cancer (BC) Journal of Clinical Oncology, 2015, 33, 582-582.	1.6	2
32	SOD1, an unexpected novel target for cancer therapy Genes and Cancer, 2014, 5, 15-21.	1.9	112
33	Inactivation of Omi/HtrA2 protease leads to the deregulation of mitochondrial Mulan E3 ubiquitin ligase and increased mitophagy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1295-1307.	4.1	54
34	SirT3 Regulates the Mitochondrial Unfolded Protein Response. Molecular and Cellular Biology, 2014, 34, 699-710.	2.3	231
35	SOD2 to SOD1 Switch in Breast Cancer. Journal of Biological Chemistry, 2014, 289, 5412-5416.	3.4	105
36	Estrogen Carcinogenesis in Breast Cancer. Endocrinology and Metabolism Clinics of North America, 2011, 40, 473-484.	3.2	72

#	Article	IF	CITATIONS
37	Skp2B Overexpression Alters a Prohibitin-p53 Axis and the Transcription of PAPP-A, the Protease of Insulin-Like Growth Factor Binding Protein 4. PLoS ONE, 2011, 6, e22456.	2.5	29
38	Skp2 and Skp2B team up against Rb and p53 Cell Division, 2011, 6, 1.	2.4	14
39	Estrogen receptor mediates a distinct mitochondrial unfolded protein response. Journal of Cell Science, 2011, 124, 1396-1402.	2.0	184
40	Skp2B attenuates p53 function by inhibiting prohibitin. EMBO Reports, 2010, 11, 220-225.	4.5	29
41	Ubiquitinâ€dependent and â€independent mitochondrial protein quality controls: implications in ageing and neurodegenerative diseases. Molecular Microbiology, 2008, 70, 1334-1341.	2.5	40
42	Tamoxifen Stimulates the Growth of Cyclin D1–Overexpressing Breast Cancer Cells by Promoting the Activation of Signal Transducer and Activator of Transcription 3. Cancer Research, 2008, 68, 852-860.	0.9	47
43	Mitochondrial Protein Quality Control by the Proteasome Involves Ubiquitination and the Protease Omi. Journal of Biological Chemistry, 2008, 283, 12681-12685.	3.4	145
44	Skp2B Stimulates Mammary Gland Development by Inhibiting REA, the Repressor of the Estrogen Receptor. Molecular and Cellular Biology, 2007, 27, 7615-7622.	2.3	18
45	Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy. Clinical Cancer Research, 2007, 13, 5665-5669.	7.0	206
46	Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene, 2005, 24, 3448-3458.	5.9	89
47	A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene, 2001, 20, 3641-3650.	5.9	52
48	The Portrait of Liver Cancer is Shaped by Mitochondrial Genetics. SSRN Electronic Journal, 0, , .	0.4	0